(Alliance News) - Shares in Barkby Group PLC rose after it announced the signing on Thursday of a second product collaboration with one of the UK's leading fertility clinics, London Women's Clinic.
The stock was trading 9.8% higher at 28.55 pence in London.
Women's health specialist Verso Biosense, owned by Barkby, will collaborate with London Women's Clinic using its uterine monitoring devices to refine the technology platform to meet the needs of fertility patients.
"We are delighted to announce our partnership with the London Women's Clinic, a true leader in providing world-class fertility treatment to women and couples," said Verso Biosense Head of Product Development Joseph Cefai.
"It is testament to the potential of our ground-breaking platform that this is the second partnership we have announced in the space of a few of weeks".
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
